Theolytics
PrivateLast Round
Grant
Mar 4, 2026
Total Funding Raised
$14.31M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Theolytics operates in Healthcare & Life Sciences and is based in Oxford. Its latest recorded funding round was a Grant round in September 2024.
Theolytics is a biotechnology company that develops oncolytic immunotherapies using a proprietary phenotypic screening platform to target and destroy cancer cells.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Theolytics Comparables
Compare Theolytics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TILT Biotherapeutics | 90% | |
| Accession Therapeutics Limited | 86% | |
| ORCA Therapeutics | 84% |
For institutional investors. Book with your work email.
Theolytics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 4, 2026 | ||||
| Grant | Sep 2, 2024 | ||||
| VC Round | Apr 17, 2024 | ||||
| Grant | Jun 1, 2022 | ||||
| Series A Extension | Jul 8, 2021 | ||||
Series A | Jan 7, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Theolytics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| Epidarex Capital | VC Round, Series A Extension, Series A |
| Oxford Science Enterprises | VC Round, Series A, Seed |
| Taiho Ventures | VC Round, Series A Extension, Series A |
| M Ventures | VC Round, Series A Extension |
| UKRI Innovate UK | Grant |
| Horizon Europe | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 4, 2026
$9.3M raised in a grant round.
- Oct 1, 2025
Matilde Saggese, MD, appointed as new CMO.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 16, 2026
Theolytics will develop targeted adenoviral candidates on Nov 16th '26.
For institutional investors. Book with your work email.
Theolytics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Theolytics's valuation, stock price, and market status.
Is Theolytics a public or private company?
Theolytics is a private company.
What is the current stock price of Theolytics?
Theolytics is a private company, so its shares have no public market price. Caplight tracks Theolytics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Theolytics worth (valuation)?
Valuation information for Theolytics is not publicly available.
Can I buy Theolytics stock?
Theolytics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Theolytics's last funding round?
Theolytics's most recent funding round was Grant on March 4, 2026.
Who are the main investors in Theolytics?
Key investors in Theolytics include Epidarex Capital, Oxford Science Enterprises, Taiho Ventures, Oxford Science Enterprises, Sound Bioventures.
Will Theolytics IPO soon?
No public IPO plans have been announced for Theolytics.
How can I track Theolytics secondary market activity?
Caplight tracks bids, offers, and trades in Theolytics's shares on secondary markets.